Q4 2018 13F Holders as of 31 Dec 2018
-
Type / Class
-
Equity / Common Shares, no par value
-
Shares outstanding
-
130,702,820
-
Number of holders
-
59
-
Total 13F shares, excl. options
-
22,212,575
-
Shares change
-
+705,959
-
Total reported value, excl. options
-
$151,471,995
-
Value change
-
+$3,053,577
-
Put/Call ratio
-
229%
-
Number of buys
-
20
-
Number of sells
-
-28
-
Price
-
$6.82
Significant Holders of Aurinia Pharmaceuticals Inc. - Common Shares, no par value (AUPH) as of Q4 2018
73 filings reported holding AUPH - Aurinia Pharmaceuticals Inc. - Common Shares, no par value as of Q4 2018.
Aurinia Pharmaceuticals Inc. - Common Shares, no par value (AUPH) has 59 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 22,212,575 shares
of 130,702,820 outstanding shares and own 17% of the company stock.
Largest 10 shareholders include FMR LLC (5,049,740 shares), NEA Management Company, LLC (4,808,483 shares), Polar Capital LLP (3,312,723 shares), FRANKLIN RESOURCES INC (1,838,500 shares), GOLDMAN SACHS GROUP INC (1,662,772 shares), Vivo Capital, LLC (1,213,290 shares), BlackRock Inc. (960,785 shares), Abingworth LLP (400,434 shares), D. E. Shaw & Co., Inc. (388,811 shares), and AMERIPRISE FINANCIAL INC (367,206 shares).
This table shows the top 59 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.